Normoparin (Heparin Sodium)

Heparin Sodium, the active ingredient in Normoparin, is an anticoagulant presented as an injectable solution for intravenous use. It is employed to prevent and treat thromboembolic disorders such as deep‑vein thrombosis and pulmonary embolism in patients at risk.

GNH USA supplies Normoparin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Normoparin acts on the coagulation cascade to manage venous thromboembolic conditions.

Deep Vein Thrombosis: prevents clot extension and recurrence in the lower limbs. Pulmonary Embolism: reduces clot burden and mortality in patients with embolic events. Surgical/Immobilization Prophylaxis: lowers the incidence of postoperative and immobilization‑related thromboembolic events.

Heparin Sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bleeding or bruising at injection sites - Mild thrombocytopenia - Hypotension during rapid infusion - Nausea or vomiting - Fever or chills - Localized pain or erythema

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT) - Spinal or epidural hematoma - Severe allergic reactions (anaphylaxis) - Massive hemorrhage - Paradoxical thrombosis - Long‑term osteopenia with prolonged use

When using Normoparin, clinicians should consider several safety measures.

Renal impairment: monitor anti‑Xa levels and adjust therapy. Hepatic disease: assess coagulation status regularly. Active bleeding: contraindicated; avoid use. Recent surgery or trauma: evaluate bleeding risk before administration. Pregnancy: use only if benefit outweighs potential fetal risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Heparin Sodium can interact with other agents affecting hemostasis.

Major Interactions (Avoid): - Concurrent use of other anticoagulants (e.g., warfarin, DOACs) - Antiplatelet drugs such as aspirin or clopidogrel - Thrombolytic agents (e.g., alteplase)

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase bleeding risk - Certain antibiotics (e.g., quinolones) can alter anticoagulant effect